ENDOIMAGE

Activatable Fluorescent Probes as Smart Diagnostic Tools for Microendoscopy Imaging

Coordinatore	THE UNIVERSITY OF EDINBURGH    more  Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL contact info Titolo: Ms. Nome: Angela Cognome: Noble Email: send email Telefono: +44 131 650 9024 Fax: +131 651 4028
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-CIG
Funding Scheme	MC-CIG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-08-01   -   2017-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF EDINBURGH  Organization address address: OLD COLLEGE, SOUTH BRIDGE city: EDINBURGH postcode: EH8 9YL contact info Titolo: Ms. Nome: Angela Cognome: Noble Email: send email Telefono: +44 131 650 9024 Fax: +131 651 4028	UK (EDINBURGH)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'My research proposal aims to develop smart fluorescent probes to be used as in-situ and real-time diagnostic tools by fibre-based confocal microendoscopy imaging with local administration. The probes will target relevant biomarkers in cancer and infection, and will be generated through a multidisciplinary approach that involves organic chemistry, cell biology, imaging and respiratory medicine. Activatable fluorescent probes are advantageous in that their fluorescent signal is triggered by a target protein, and hence they emit fluorescence ONLY AFTER interaction with the defined target (e.g. enzyme) or environment. This strategy leads to optimum signal-to-noise ratios with increased sensitivity over other optical imaging approaches and enables their use in small concentrations with no systemic administration, hence reducing any potential adverse effects and facilitating the translation to clinical applications. The current proposal will focus on two projects: 1) enzyme-activatable probes for imaging endoscopically-accesible cancer (initially targeted at lung cancer, but later also applicable to oesophagus and pancreas cancer), and 2) environment-sensitive fluorescent probes for the detection of fungal infection in lungs (i.e. pulmonary aspergillosis).'